The 5J8 DMAb was expressed at µg/mL levels in serum of both nude and immune-competent mice. Serum DMAb produced from muscle in vivo were functional in vitro -with the ability to bind influenza HA, block hemagglutination of red blood cells, and neutralize influenza virus. Serum DMAb expression levels approximate those required for protection. Influenza challenge studies of mice treated with 5J8 DMAb are underway.
434.
Adoptive Respiratory syncytial virus (RSV) is a massive medical burden in infants and children worldwide, and an effective and safe RSV vaccine remains an unmet need. Here we report a novel vaccination strategy to deliver a pDNA vaccine encoding RSV-F using a surface electroporation device (SEP) to target epidermal cells in clinically relevant experimental models. We demonstrate the ability of this strategy to target epidermal Langerhans cells, and elicit robust cellular and humoral immune responses. In the cotton rat challenge model we demonstrate complete resistance to pulmonary infection after delivering a single low dose of vaccine. In contrast to the formalin-inactivated RSV (FI-RSV) vaccine there was no enhanced lung inflammation upon virus challenge after pDNA vaccination. In summary the data presented outlines the pre-clinical development of a highly efficacious, tolerable and safe non-replicating vaccine strategy against RSV.
436.
Developing Results: Immunization of mice with MERS-vaccine induced strong humoral and cellular responses. Mice produced strong binding antibody (bAb) titers and nAb titers. A strong, polyfunctional, CD4 and CD8 T cell response was detected against multiple epitopes across the MERS spike protein. Immunization of dromedary camels induced the production of MERS spike specific antibodies and nAbs. Immunization of NHPs induced strong bAb titers and nAb titers and a strong CD4 and CD8 T cell response. NHPs immunized with multiple vaccination regimens were also protected from signs of disease upon challenge with infectious MERS-CoV and showed a greater than 3 log reduction in viral load after challenge compared to unvaccinated animals.
Conclusions: A consensus DNA MERS-vaccine was able to generate both a strong T cell and neutralizing antibody response in multiple animal models, including camels, a natural host for MERSCoV and a probable source of human infection. MERS-vaccine was also able to protect NHPs from an infectious MERS-CoV challenge. These results demonstrate the promise of this consensus DNA MERSvaccine as a candidate for vaccine development.
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